Business Context and Reporting Period
This Form 8-K was filed by pSivida Corp. on July 10, 2017. The filing reports the entry into a definitive material agreement on the same date. The registrant is a Delaware corporation with principal executive offices in Watertown, MA.
Key Financial Metrics and Agreement Terms
The filing details a Second Amended and Restated Collaboration Agreement with Alimera Sciences, Inc. regarding the products ILUVIEN and Durasert. Key financial terms include:
- Royalty Structure: Conversion from a profit-sharing arrangement to a tiered sales-based royalty on global net revenues for ILUVIEN (Diabetic Macular Edema). Royalties start at 2% and increase to 6% upon the earliest of January 1, 2019, EU marketing approval for posterior segment uveitis, or one year from the EU filing for such approval. Royalties rise to 8% on total ILUVIEN revenues exceeding $75 million in any calendar year.
- Loss Forgiveness: Alimera forgave $10 million of the Company's share of previous losses associated with ILUVIEN commercialization (capped at $25 million).
- Recoverable Losses: Alimera retains the right to recover $15 million of previous losses as an offset to future royalty payments. An additional $5 million of this remaining balance will be forgiven upon EU approval for posterior uveitis or by January 1, 2020, whichever occurs first.
- Cash Settlement: If recoverable amounts are less than $5 million at the specified trigger date, Alimera must pay the difference in cash to the Company.
Material Changes Versus Prior Period
The New Collaboration Agreement significantly alters the commercial and financial relationship established under the Prior Collaboration Agreement (dated March 14, 2008):
- Revenue Recognition: Shifted from a country-by-country net profit sharing model to a global net revenue-based royalty model effective July 1, 2017.
- Geographic Rights: Alimera received rights to the Company's Durasert three-year treatment for posterior segment uveitis in the EMEA region. Alimera also gained the right to pursue an indication for posterior segment uveitis for ILUVIEN in the EMEA.
- Regulatory Actions: The Company withdrew its marketing approval application and orphan drug designation for posterior segment uveitis in the European Union, transferring these obligations to Alimera.
Outlook, Risks, and Contingencies
Future financial outcomes are contingent upon specific regulatory and sales milestones:
- Regulatory Milestones: Royalty rate increases and loss forgiveness triggers depend on Alimera receiving EU marketing approval for ILUVIEN for posterior segment uveitis or filing the relevant application.
- Development Obligations: Alimera is responsible for filing a Type II variation for ILUVIEN for posterior segment uveitis in 17 EU countries where the drug is currently approved for DME.
- Commercial Rights: The Company retained commercialization rights for posterior segment uveitis in all countries outside the EMEA, including the United States.
Investor Verification Checklist
- Verify the exact effective date of the royalty tier changes (July 1, 2017) and the specific triggers for the 6% and 8% royalty rates.
- Confirm the status of the $15 million recoverable loss balance and the conditions required for the additional $5 million forgiveness.
- Review the full text of the New Collaboration Agreement (to be filed as an exhibit to the Form 10-K for the fiscal year ended June 30, 2017) for detailed definitions of "net revenues" and "net profits."
- Monitor Alimera's progress on the Type II variation filing for ILUVIEN in the 17 specified EU countries.